MEI Pharma [thank you Novogen] in the US have partnered up with the Swiss Helsinn Group which means a trade-off has been made between potential royalty stream and making immediate finance available for advancing clinical trials; at the moment both parties are happy with the arrangement.
Something that the current version of Novogen could consider?
https://www.helsinn.com/our-business/partnerships/current-partnership/
